It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.
Similar Posts
Inactive Ingredients Database Download
Data updated through July 2024Right Value Drug Stores, LLC. Irving, TX. 483 issued 07/18/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 07/18/2025
Short Title (70 char) Right Value Drug Stores, LLC. Irving, TX. 483 issued 07/18/2025
FEI Number 3010589333
Firm Name Right Value Drug Stores, LLC
Record Type 483
State TX
Establishment Type OutsourciEarly Alert: Trividia Health Issues Correction for TRUE METRIX Blood Glucose Monitoring Systems
Trividia recommends that device users who receive an E-5 error code and are experiencing symptoms of high glucose should seek medical care immediatelyOlympus Expands Voluntary Recall for ViziShot 2 FLEX (19G) EBUS -TBNA Needles
CENTER VALLEY, Pa., (January 16, 2026) — Olympus Corporation has announced the expansion of a previous global medical device removal action for ViziShot 2 FLEX (19G) EBUS -TBNA needles (“ViziShot 2 FLEX”) after receiving and investigating complaints of device components ejecting or detaching duringAdvancing Real-World Evidence Program
Advancing Real-World Evidence ProgramClinical Outcome Assessments (COA) Qualification Program Resources
Resources and information for requestors interested in CDER’s Clinical Outcome Assessments (COA) Qualification Program.This update contains the Letter of Intent Template for the COA Qualification Program, as described under section 507 of the Federal Food, Drug, and Cosmetic Act.